Topics
Glioblastoma | Treatment | Targeted therapy | Angiogenes isinhibitors | Efficacy
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Angiogenes isinhibitors > Efficacy
Zhang JF, Okai B, Iovoli A,
Goulenko V, Attwood K, Lim J, Hess RM, Abad AP, Prasad D,
Fenstermaker RA.
Bevacizumab
and gamma knife radiosurgery for first-recurrence glioblastoma.
J
Neurooncol. 2024
Jan 4. doi:
10.1007/s11060-023-04524-y. PMID:
38175460. Observational study. ˍ
*Sferruzza G, Malcangi M, Bosco L, Finocchiaro G.
Reassessing
the efficacy of bevacizumab in newly diagnosed glioblastoma: A
systematic review and external pseudodata-based
analysis.
Neurooncol
Adv. 2024 Jan 22;6(1):vdad174. doi:
10.1093/noajnl/vdad174. PMID:
38390032. Review. ˍ
Habibi MA, Ghorbani M, Esmaeilian S, Tajvidi F, Nekutalaban P,
Boskabadi AR, Alemi F, Zafari R, Mirjani MS, Eazi S, Minaee P.
Stereotactic radiosurgery versus
combined stereotactic radiosurgery and bevacizumab for recurrent
glioblastoma; a systematic review and meta-analysis of survival.
Neurosurg
Rev. 2024 Jul 13;47(1):323. doi:
10.1007/s10143-024-02585-9. PMID:
39002028. Review; Meta-analysis˰
ˍ
Lee Y, Lee E, Roh TH, Kim SH.
Bevacizumab
Alone Versus Bevacizumab Plus Irinotecan in Patients With
Recurrent Glioblastoma: A Nationwide Population-Based Study.
J
Korean Med Sci. 2024 Jul 29;39(34):e244. doi:
10.3346/jkms.2024.39.e244. PMID:
39228184. Observational study. ˍ
Habibi MA, Shad N, Mirjnani MS, Fasihi S, Sadeghi S, Karami S,
Ahmadvand MH, Delbari P, Zare AH, Zare AH, Alavi SAN.
Is
add-on Bevacizumab therapy to Temozolomide and radiotherapy
associated with clinical utility for newly diagnosed Glioblastoma?
A systematic review and meta-analysis.
Neurosurg
Rev. 2024 Aug 20;47(1):445. doi:
10.1007/s10143-024-02667-8. PMID:
39162874. Review; Meta-analysis˰
ˍ
*Yang F, Wang L, Zhao W, Wang S, Li J, Sun A, Wang M, Wang Z, Chen
Z, Heng X.
A Systematic Review and
Meta-Analysis on the Effectiveness of Radiotherapy and
Temozolomide Treatment With or Without Bevacizumab in Patients
With Glioblastoma Multiforme.
Neurol
India. 2024 Aug 31;72(4):700-707. doi:
10.4103/neurol-india.Neurol-India-D-23-00346. PMID:
39216020. Review; Meta-Analysis. ˍ
Zhong W, Mao J, Wu D, Peng J, Ye W.
The
efficacy of stereotactic radiotherapy followed by bevacizumab and
temozolomide in the treatment of recurrent glioblastoma: a case
report.
Front
Pharmacol. 2024 Sep 4;15:1401000. doi:
10.3389/fphar.2024.1401000. PMID:
39295944. Case report. ˍ
**Alyasova AV, Ben Ammar AM, Zarkua VT, Rerberg AG.
A
case report of successful combined intra-arterial immunotherapy
and cytokine genetic therapy treatment in a patient with recurrent
glioblastoma.
Chin
Clin Oncol. 2024 Sep 6:cco-24-34. doi:
10.21037/cco-24-34. PMID:
39260431. Case report. ˍ
*Laviv Y, Regev O, Kanner AA, Fichman S, Limon D, Siegal T,
Yust-Katz S, Benouaich-Amiel A.
Stem
the blood flow: beneficial impact of bevacizumab on survival of
subventricular zone glioblastoma patients.
J
Neurooncol. 2024 Sep 24. doi:
10.1007/s11060-024-04828-7. PMID:
39316315.. Observational study. ˍ
Motamed-Sanaye A, Mortezaei A, Afshari AR, Saadatian Z, Faraji AH,
Sheehan JP, Mokhtari AM.
Angiogenesis
inhibitors effects on overall survival and
progression-free survival in newly
diagnosed primary glioblastoma multiforme: a
meta-analysis of twelve randomized
clinical trials.
J
Neurooncol. 2024 Dec 5. doi:
10.1007/s11060-024-04865-2. PMID:
39636552. Meta-analysis˰
ˍ